SUMMARY Recently, ergonovine has been suggested to evoke coronary artery spasm in patients with variant angina. The purpose of our investigation was to study clinical, hemodynamic, electrocardiographic (ECG), and coronary angiographic effects of ergonovine in 60 selected patients undergoing angiography. The patients were equally divided, 30 with coronary artery disease (CAD), lesions 250%, and 30 with minimal (<50%) or no CAD. Ergonovine (0.05 to 0.4 mg i.v. bolus) was given while each patient was monitored for symptoms and changes in ECG, heart rate, QTc intervals, blood pressure, and coronary diameter. After ergonovine, 18 patients developed chest pain, eight of whom had associated STsegment shifts (>-I mm tion were specifically excluded. No studies were performed in amenorrheic, premenopausal females.
implied the ergonovine test may be clinically useful and safe, but interest waned. Renewed interest in the potential coronary actions of this agent developed following a recent preliminary report by Heupler and co-workers" suggesting that ergonovine may provoke attacks of "variant" angina. Additionally, new evidence by Maseri9' 10 and Weiner" now supports coronary arterial spasm as an important pathophysiologic mechanism in patients with variant angina and possibly in the production of myocardial ischemia in other patients. These reports stimulated us to examine the effects of ergonovine in patients with chest pain, since a provocative test to identify patients with coronary spasm would be clinically useful. The purpose of this study was to evaluate clinical, electrocardiographic, and coronary angiographic responses to ergonovine maleate in patients with and without angiographic evidence of coronary artery disease. Methods Studies were conducted in 60 patients (56 males and 4 females) with a mean age of 52 years (range 28-67) referred for cardiac catheterization studies to further evaluate a chest pain syndrome. Patients with recent myocardial infarction (less than 3 months), left main coronary obstruction (greater than 50%), aortic stenosis, or prior coronary revasculariza-147 mm Hg (P < 0.01). The mean diameter of 164 coronary arteries examined decreased 18% (P < 0.001) after ergonovine. Five patients with documented variant angina all developed typical chest pain and ST-segment shifts following ergonovine. Spasm of the anterior descending evoked with ergonovine was similar in location and magnitude to spasm occurring during spontaneous pain ( tion were specifically excluded. No studies were performed in amenorrheic, premenopausal females.
Each patient was studied after an overnight fast during which all cardiac drugs were temporarily discontinued. A written informed consent was obtained from each patient, specifically in regard to the use of ergonovine, and a detailed explanation of its known complications including stroke and myocardial infarction. Following multilead electrocardiographic recording and pressure monitoring, selective coronary angiography was performed in each patient. In patients who had electrocardiographic evidence of heart block during an acute attack of variant angina, the method was altered to include the addition of a temporary pacing catheter in the right heart.
Ergonovine maleate (Ergotrate, Lilly) 0.05 to 0.4 mg was given intravenously (rapid bolus injection) as heart rate (HR), systemic arterial blood pressure (BP), and electrocardiograms were continuously monitored for 10-15 min. Repeat coronary angiography was performed (33 patients) between 5 and 10 min after ergonovine injection, or during chest pain and/or ST-segment shifts when these responses occurred. Since only one set of coronary angiograms were obtained following ergonovine, it is apparent that our meth,ods would not identify variation in the degree and location of coronary artery spasm during an attack of variant angina.
Before and after ergonovine, HR and corrected QT intervals (QTc) were measured and averaged over at least 10 consecutive beats, and systolic BP was recorded from the aorta or brachial artery. The ST segment shifts were analyzed by measuring average ST segment shift from the PR segment. Significant shifts _ 1.0 mm from the control measurements were tabulated.
Coronary artery diameters were measured at readily identifiable branch points from appropriately selected projected cine frames. The following branch points were used: the left main before its bifurcation; the anterior descending before the first septal perforator; the circumflex before the obtuse marginal branch; the right before the acute marginal branch, and the obtuse marginal branch just after its take-off. In any given patient, these selective angiograms were obtained in the same projection at the same tube to tabletop and cardiac apex to tabletop distances before and after ergonovine.
Cine films were analyzed on the same projector (Tagarno, Model #3500). Matched end-diastolic frames were compared and measurements of the coronary artery diameter made with calipers. With this technique, we have found that reproducible measurements can be made to ±0.5 mm. If coronary artery spasm occurred at areas other than the measured branch points, no attempt was made to quantitate the narrowing. Subtotal or totally occluded vessels could not be accurately quantitated.
The patients were questioned regarding the presence of symptoms following ergonovine. When present, they were carefully recorded in detail. These findings along with electrocardiographic (ST segments, QTc, and dysrhythmias), hemodynamic (HR and BP), and coronary artery diameter changes occurring after ergonovine were tabulated in patients with coronary artery disease (CAD) and with minimal or no CAD. The double product was calculated as HR X systolic BP. Mean values for HR, QTc, systolic BP, double product and coronary artery diameter were calculated, and the statistical significance of the pre-to postergonovine comparisons were analyzed using Student's ttest for paired data.
Results

Clinical and Electrocardiographic Responses
The clinical and ECG responses to ergonovine in patients with CAD (defined as >50% obstruction of at least one major vessel) are compared with patients demonstrating minimal (<50%) or no CAD in table 1 studied whose clinical presentation was variant angina (cases 1-5). In two of the three other patients with this combination of responses, variant angina was suspected but not documented previously. Heart rate and blood pressure findings occurring after ergonovine are shown in figure 1. Heart rate was not significantly influenced by ergonovine (mean 73 beats/min before versus 74 beats/min after). Arterial systolic BP after ergonovine increased from a mean of 133 to 147 mm Hg, an 11% increase (P < 0.01). Nine patients developed a systolic BP rise >30 mm Hg. Six of these had a history of hypertension. In one other patient (case 1, table 2) a 30 mm Hg decrease in systolic BP occurred during complete heart block with chest pain. The double product increased from a mean of 9,709 to 10,878 mm Hg/min (P < 0.01).
Angiographic Studies
The influence of ergonovine on coronary artery diameter in 33 patients (164 arteries) is shown in figure 2 . Mean projected coronary diameter decreased from 6.7 to 5.5 mm, an 18% decrease (P < 0.001). An illustrative example of the typical changes in coronary diameter before and after ergonovine is shown in figure 3 . In six patients (cases 1-3, 5, 7, and 8, tables 2 and 3) with ST-segment shifts (four with documented variant angina and two without) restudied with coronary angiography during ergonovine pain, coronary diameter decreased 24% (mean) compared to 15% in the group without ST changes. While the differences between these patient subgroups were not statistically significant Coronary angiographic observations were also made during spontaneous chest pain in cases 1 and 3 before ergonovine. Both patients had variant angina. Four matched frames from the cine angiograms of their coronary arteries are shown in figures 4 and 5. Each patient developed ST shifts during chest pain. With a spontaneous episode of pain, marked left anterior descending spasm was noted. After pain resolved without nitroglycerin, the angiograms were repeated and coronary size was restored to pre-angina levels. Ergonovine then evoked pain, again associated with anterior descending spasm. Following nitroglycerin, pain resolved and the anterior descending diameter returned to control. Thus, we observed a close similarity between spontaneous and ergonovine evoked chest pain with ST shifts and anterior descending spasm in two variant angina patients. It is possible that a larger dose of ergonovine might produce a higher incidence of myocardial ischemia. Our average dose was 0.26 mg (0.05 to 0.4) compared to Stein's average dose of 0.4 mg (0.2 to 0.6).
Discussion
Despite the limitations, ergonovine injection seems to have a dramatic effect in our patients presenting with the clinical syndrome of variant angina. If we use the criteria of =1 mm ST segment shift following ergonovine, we were able to identify all five of the patients studied with previously documented variant angina (cases 1-5, table 2). Three additional patients (cases 6-8, table 2) with severe CAD also had ST-segment responses (two of three presented with recurrent episodes of rest pain, but did not have documented ST-segment elevation with pain). All three patients had high grade proximal coronary narrowings. Two of these (cases 7 and 8) had repeat coronary arteriography during ergo- Ergonovine caused an increase in systolic blood pressure, decrease in coronary diameter, and had a variable, but statistically insignificant effect on heart rate in our entire group of 60 patients. The rise in systolic blood pressure can be explained by the known vasoconstrictor action of ergonovine.1-' Although a significant rise in the double product after ergonovine was observed, there was no consistent association between the double product and the development of chest pain after ergonovine. This suggests that the development of chest pain was not related to an increased myocardial oxygen demand. The decrease in coronary artery diameter may be due to a direct effect of ergonovine or a reflex change due to an increase in blood pressure. However, there was no association between coronary diameter changes after ergonovine in patients whose blood pressure increased or remained unchanged. The lack of significant decrease in heart rate following ergonovine supports the hypothesis that ergonovine blocks the baroreceptor reflex.
In respect to the use of the ergonovine test, it is questionable whether or not the test can yet be labeled as a routine in the investigation of patients with chest pain. Our results support previously reported experiences suggesting that ergonovine can be given to selected patients with coronary artery disease. The data at this time, however, do not establish the ergonovine test as being entirely safe. The clinical usefulness and safety of intravenous ergonovine in patients with various chest pain syndromes need to be established in larger clinical trials. A few reports of serious complications following ergonovine indicates the need for caution when using this drug. Reported complications28-35 have included severe hypertension, seizures, premature ventricular contractions, myocardial infarction, intracerebral hemorrhage, and death. In our group of patients, intravenous ergonovine produced no serious complications, myocardial infarction, stroke, or cardiac arrest. All patients developing ST-segment shifts were evaluated with serial measurements of CPK-MB, electrocardiograms and technetium-99m pyrophosphate myocardial scintigrams following ergonovine administration. No detectable myocardial damage was observed in these patients. Severe hypertension (systolic BP rise greater than 50 mm Hg) occurred in two (3%) patients who responded to nitroglycerin.
Hypotension (systolic BP drop of 30 mm Hg with complete heart block) occurred in one patient, and was reversed with nitroglycerin.
Our clinical experience in these 60 patients has led to the development of the following protocol for use of intravenous ergonovine. Using this protocol, no patient has developed lasting ill effects during or after the injection of ergonovine. We strongly warn against the use of ergonovine in a setting in which proper safety precautions are not available, particularly in the presence of severe CAD. Prolonged chest pain with myocardial infarction may occur as a complication of administration of ergonovine, although this complication was not observed in any of our patients.
In summary, the effects of ergonovine on 60 patients (30 with CAD and 30 with minimal or no CAD) were similar. Following administration of ergonovine, blood pressure rose, coronary artery diameter decreased, heart rate and QTc remained unchanged. Using ST-segment shift 2 1 mm, the ergonovine test identified five of five patients with previously documented variant angina. The test appears sensitive to detect patients with variant angina. Spontaneous spasm of the left anterior descending coronary artery occurred in two variant angina patients during coronary arteriography. The arteriographic findings were similar following ergonovine. This suggests that spontaneous and ergonovine induced coronary spasms were similar. No permanent ill effects developed following ergonovine, but we warn against its use in patients with severe CAD since prolonged pain and myocardial infarction may result.
